Jubilant Pharmova reported its Q2 FY26 results, highlighting a revenue of ₹19,664 million. The company also completed the sale of its Active Pharmaceutical Ingredients (API) business to Jubilant Biosys Limited on September 1, 2025. Excluding the API business, management and other support services are now the company’s continuing operations. A loss of ₹1,025 million was recorded for the quarter.
Financial Performance Overview
Jubilant Pharmova announced its financial results for Q2 FY26, with a total revenue of ₹19,664 million. Expenses totaled ₹17,800 million for the quarter. The company recorded a net loss of ₹1,025 million.
Segmental Performance
Here’s a breakdown of the revenue from various segments:
- Radiopharma: ₹8,971 million
- Allergy Immunotherapy: ₹1,940 million
- Contract Development and Manufacturing Organization (CDMO) – Sterile Injectables: ₹4,115 million
- Contract Research, Development and Manufacturing Organization: ₹3,125 million
- Generics: ₹1,670 million
Sale of API Business
The sale of the Active Pharmaceutical Ingredients (API) business to Jubilant Biosys Limited, a wholly-owned subsidiary, was completed on September 1, 2025. This transaction has been classified as a discontinued operation. The continuing operations of the company now mainly comprise management and other support services.
Impact of Discontinued Operations
The discontinued API business contributed a revenue of ₹978 million for Q2 FY26 until its sale on September 1, 2025. Net profit/loss for the period was ₹416 million.
Tax Regime Change
Jubilant Pharmova intends to transition to the New Tax Regime starting from the financial year 2026-27, in accordance with Section 115BAA of the Income-tax Act, 1961.
Source: BSE